Home
A warm welcome

Spirogene was established in 2007 to commercialise research from Professor David Hampson of Murdoch University on an emerging poultry disease, Avian Intestinal Spirochaetosis.

In 2008, Spirogene expanded its research focus to include Swine Dysentery, a significant disease of pigs caused by pathogenic Brachyspira hyodysenteriae.

Through the support of Perth-based Stone Ridge Ventures and the Murdoch WestScheme Enterprise partnership, Spirogene has embarked on an ambitious research programme to translate more than 20 years of research experience into real and sustainable solutions for production animals.

The founding CEO of Spirogene was Dr Alistair Murdoch, a very well respected Veterinarian who tragically passed away in 2011. Alistair managed to position Spirogene with both an international alliance to develop a vaccine to Swine Dysentery and a partnership with Prionics in Europe to develop a diagnostic test for Swine Dysentery.

The Spirogene research team working with Professor David Hampson's team is small, but focused. We draw on our in-depth understanding of Brachyspira genomics and epidemiology to discover and deliver vaccine candidates with improved efficacy profiles, in accordance with strict GLP guidelines.

We thank you for your interest in Spirogene and look forward to collaborating with you in the future.

Dr Stewart Washer

CEO, Spirogene

Spirogene is an Australian R&D company focused on developing sustainable solutions for animal health.

Spirogene is currently focused on developing novel vaccines and diagnostics for diseases caused by the spirochaetal bacteria Brachyspira. Brachyspira species are anaerobic, intestinal pathogens of production animals resulting in significant economic and production losses. Brachyspira species causes Swine Dysentery in Pigs and Avian Intestinal Spirochaetosis in Poultry.

Spirogene builds on more than 20 years of research experience in Brachyspira through Professor David Hampson of Murdoch University, a world authority on Brachyspira. Integrating bioinformatics, genomics and proteomics, Spirogene has embarked on an intensive R&D programme to develop novel vaccines and diagnostic solutions for both Swine Dysentery and Avian Intestinal Spirochaetosis.

Spirogene has also commenced a separate R&D programme to develop a novel platform for drug residue and pathogen detection. The project, in collaboration with Assoc. Professor Rob Trengove from the Murdoch University Separation Science and Metabolomics Laboratory, will use cutting-edge Metabolomics to develop the next generation of mass spectrometry platform for the detection of drug residues and pathogens in both pigs and poultry.

News

Spirogene secures Commercial Partner for Swine Dysentery Project

(2009) Spirogene has successfully secured a commercial agreement with a European-based Animal Health Pharmaceutical company to develop and commercialise its Swine Dysentery vaccine candidates.

Spirogene granted new patents in the USA and Europe

(2009) Spirogene has been granted two additional patents in the USA and Europe.

Spirogene presents Epidemiology Data at major poultry conference

(2009) Spirogene presents new epidemiology and testing data on AIS to the AGM of the Association of Veterinarians in Egg Production at the International Poultry Expo in Atlanta, Georgia.

Spirogene extends Testing Program

(2009) Spirogene has extended its epidemiology and testing programme for Avian Intestinal Spirochaetosis in the USA and the UK in collaboration with leading poultry specialists.

Spirogene secures second tranche of COMET assistance

(2009) Spirogene has received additional COMET assistance from AusIndustry for its AIS research programme.

Spirogene to develop vaccines for Swine Dysentery

(2008) Spirogene has successfully raised additional development capital from Stone Ridge Ventures to commercialise vaccine IP for Swine Dysentery caused by Brachyspira hyodysenteriae.

Spirogene receives grant from Commercial Ready

(2008) Spirogene received matching funds from the competitive AusIndustry Commercial Ready Programme to develop its product pipelines for AIS.

Spirogene receives COMET assistance

(2008) Spirogene received COMET assistance from AusIndustry to assist in the commercialisation of its vaccine and diagnostic kit for AIS

Spirogene formed to commercialise vaccines for AIS

(2007) Murdoch University and Perth-based Stone Ridge Ventures invested AUD $500,000 from the Murdoch Westscheme Enterprise Partnership Fund into Spirogene, a new R&D company focused on the development of vaccines and diagnostic for Avian Intestinal Spirochaetosis.